Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma Europe (APEL) has reported results from the Phase III AFFIRM study in which MDV3100 demonstrated a statistically significant improvement in overall survival with a median improvement over placebo of 4.8 months.
Subscribe to our email newsletter
The investigational drug MDV3100 extended life by nearly five months, compared to placebo, in men with advanced prostate cancer, previously treated with chemotherapy.
The study also concluded that MDV3100 was generally well tolerated by patients and met all secondary endpoints.
Secondary endpoints in the study included radiographic progression-free survival (rPFS) and time to prostate-specific antigen (PSA) progression.
MDV3100, developed by Astellas Pharma and Medivation, is an oral androgen-receptor signalling inhibitor in clinical development for advanced prostate cancer.
A new European survey reveals 99% of oncologists and urologists feel there is a need for new treatments in advanced prostate cancer.